AYR Wellness to Hold First Quarter 2024 Conference Call on May 15 at 8:30 a.m. ET
MIAMI, April 11, 2024 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading […]
MariMed Closes Acquisition of Thrive Dispensary in Casey, The Company’s Fifth Illinois Dispensary
NORWOOD, Mass., April 11, 2024 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator […]
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary […]
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company […]
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company […]
Crown Castle Highlights Actions Underway to Create Stronger and More Valuable Company
Files Definitive Proxy Materials and Mails Letter to Shareholders Urges Shareholders to Vote “FOR” Only Crown Castle’s 13 Qualified and […]
Rail Vision Received $1 Million Order out of a Contract Valued at Up to $5 Million with Leading US-Based Rail and Leasing Services Company
Ra’anana, Israel, April 11, 2024 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the […]
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced […]
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical […]
Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call
DURHAM, N.C., April 11, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), […]
